Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury? - Full Text View

Purpose

The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.

Condition	Intervention	Phase
Cardiovascular Disease Ischemia-Reperfusion Injury	Drug: Dipyridamole Drug: caffeine	Phase 4

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?

Resource links provided by NLM:

MedlinePlus related topics: Caffeine Exercise and Physical Fitness

Drug Information available for: Dipyridamole

U.S. FDA Resources

Further study details as provided by Radboud University:

Primary Outcome Measures:

Percentage difference in Annexin A5 targetting between experimental and control thenar muscle at 60 and 240 minutes after reperfusion [ Time Frame: 60 and 240 minutes after ischemic exercise ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Plasma dipyridamole concentration [ Time Frame: at the morning of day 7 of treatment with dipyridamole/placebo ] [ Designated as safety issue: No ]
ENT transport activity (before and after treatment with dipyridamole 200mg, twice daily, for seven days) [ Time Frame: before start of treatment (dipyridamol/placebo) and in the morning of day 7 of treatment (placebo/dipyridamol) ] [ Designated as safety issue: No ]
Workload (duration of exercise and developed force) [ Time Frame: during 10 minutes of ischemic exercise ] [ Designated as safety issue: No ]

Enrollment:	20
Study Start Date:	January 2007
Study Completion Date:	April 2007
Primary Completion Date:	March 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1 dipyridamol during 7 days and before ischemic exercise caffeine 4mg/kg	Drug: Dipyridamole Dipyridamole 2x200mg 7day per os Other Name: persatin Drug: caffeine caffeine 4mg/kg iv Other Name: n.a.
Placebo Comparator: 2 dipyridamol during 7 days and before ischemic exercise placebo	Drug: Dipyridamole Dipyridamole 2x200mg 7day per os Other Name: persatin

Detailed Description:

Dipyridamole has been proven to reduce targeting of Annexin A5 in responses to ischemic exercise, indicating protection against ischemia-reperfusion injury in humans (pharmacological preconditioning). Dipyridamole increases the endogenous adenosine level by inhibition of the nucleoside transporter (ENT-1). Activation of the adenosine receptor protects against ischemia-reperfusion injury. We hypothesize that endogenous adenosine mediates the protective effect of dipyridamole against ischemia-reperfusion injury. Therefore the adenosine receptor antagonist caffeine will reduce the benefit of dipyridamole on forearm ischemia-reperfusion injury.

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Male
Age between 18-50yr.

Exclusion Criteria:

cardiovascular disease
hypertension (systole > 140 mmHg, diastole > 90 mmHg)
hypercholesterolemia (random total cholesterol > 6.5 mmol/l)
diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists)
participation in any clinical trial during the last 60 days prior to this study.
administration of two doses of Annexin A5 (0,1mg; 450MBq) during the last 5 years prior to this study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00430170

Locations

Netherlands
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500hb

Sponsors and Collaborators

Radboud University

Investigators

Principal Investigator:

Gerard Rongen, MD PhD

Radboud University

More Information

Publications:

Riksen NP, Oyen WJ, Ramakers BP, Van den Broek PH, Engbersen R, Boerman OC, Smits P, Rongen GA. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther. 2005 Jul;78(1):52-9.

Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. Epub 2004 Dec 27.

Responsible Party:	G Rongen, dept Pharmacology Toxicology
ClinicalTrials.gov Identifier:	NCT00430170 History of Changes
Other Study ID Numbers:	dipy001
Study First Received:	January 31, 2007
Last Updated:	July 28, 2008
Health Authority:	Netherlands: Medical Ethics Review Committee (METC) Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:

ischemia-reperfusion injury
adenosine
dipyridamole
caffeine

Additional relevant MeSH terms:

Cardiovascular Diseases
Ischemia
Reperfusion Injury
Pathologic Processes
Vascular Diseases
Postoperative Complications
Caffeine
Dipyridamole
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents

Therapeutic Uses
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Platelet Aggregation Inhibitors
Hematologic Agents
Vasodilator Agents
Cardiovascular Agents

ClinicalTrials.gov processed this record on June 17, 2013